Rafael Pharmaceuticals Inc. said FDA has granted an orphan drug designation to CPI-613, the company’s lead Altered Energy Metabolism Directed drug candidate, for the treatment of peripheral T-cell lymphoma.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe